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Effect of Macrophage Depletion on Immune Effector
Mechanisms during Corneal Allograft Rejection in Rats
Tanja P. A. M. Slegers,1,2 Paulo F. Torres,1,3 Lidy Broersma,1 Nico van Rooijen,4
Gabriel van Rij,5 and Ruth van der Gaag1
PURPOSE. In rats, corneal allograft rejection is delayed for at least 100 days by clodronate liposomes.
These liposomes selectively deplete macrophages. To investigate the immunologic basis for ab-
sence of graft rejection in treated rats, the effect of these liposomes on the generation of cytotoxic
T lymphocytes (CTLs) and antibody production after orthotopic corneal allotransplantation was
determined.
METHODS. Transplantations of corneal buttons from PVG rats were performed in AO rats. After
surgery, one group received clodronate liposomes subconjunctivally at five time points, and the
other group remained untreated. On postoperative day (POD) 3, 7, 12, or 17, rats were killed, the
presence of CTLs was investigated at three different anatomic locations, and antibodies against
donor antigens were tested.
RESULTS. No significant differences were found between the groups tested 3 and 7 days after
surgery. But on POD 12 (the time of onset of rejection in the untreated group) and on POD 17, the
CTL activities detected in the submandibular lymph nodes (P # 0.008) and the spleen (P # 0.009)
were significantly less in the treated groups compared with the untreated groups. In the untreated
groups complement-independent antibodies were present only on POD 17, whereas no antibodies
were found in the treated rats.
CONCLUSIONS. Local treatment with clodronate liposomes was shown to downregulate local and
systemic CTL responses and to prevent the generation of antibodies. Local depletion of macro-
phages in the initiation phase of the immune response appears to lead to a less vigorous attack on
the grafted tissue and therefore to promote graft survival. (Invest Ophthalmol Vis Sci. 2000;41:
2239–2247)
As a remedy for corneal defects, corneal transplantationappears to be very effective. Therefore, each year alarge number of corneal transplantations is performed,
with an estimated 3-year failure rate at 10% to 40%.1–3 The
major cause for corneal graft failure is immunologic rejection
of foreign tissue. The purpose of topical or systemic adminis-
tration of corticosteroids is to suppress this immune response,
but it is not always efficient. To improve the outcome of
high-risk corneal grafts in particular, research is performed to
find new therapies that are more effective than those currently
used. Promising studies have been performed using oral immu-
nization,4 blocking of particular cytokines or adhesion mole-
cules,5–7 or local blocking with anti-CD4.8
Histopathologic studies of corneal graft rejection show an
influx of not only T lymphocytes but also many macrophages.9
Although the current opinion is that rejection is mediated by T
lymphocytes, Van der Veen et al.10 performed a study to
determine the contribution of the macrophage to immunologic
corneal graft rejection in high-risk rats. Using dichloromethyl-
ene diphosphonate (clodronate)–containing liposomes, mac-
rophages could be selectively depleted. Subconjunctival ad-
ministration of these liposomes after orthotopic corneal
transplantation to recipient rats with a history of corneal in-
flammation, surprisingly resulted in complete graft survival in
all treated rats for a follow-up period of 100 days, whereas the
control group rejected the grafts between 12 and 17 days after
surgery. Therefore, macrophages also seem to play an impor-
tant role in corneal graft rejection.
It remains to be determined how the clodronate lipo-
somes interfered in the rejection process. With regard to the
various functions of macrophages, they can be involved in both
the afferent and the efferent arc of the immune response
leading to graft rejection. Through processing and presentation
of foreign antigen to T lymphocytes they can participate in the
afferent arc, but they are also able to play the role of effector
cells and destroy the graft.11,12
In this study, we used a different rat strain combination
without prior induction of keratitis to validate the clodronate
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liposome treatment. To unravel the immunologic basis for the
absence of graft rejection in clodronate liposome–treated rats
we used this strain combination to measure the cytotoxic T
lymphocyte (CTL) and antibody responses from postoperative
days (PODs) 3 to 17.
METHODS
Animals
Inbred male AO/OlaHsd (RT1u) and PVG/OlaHsd (RT1c) rats
were obtained from Harlan UK (Bicester, UK). At the time of
transplantation, AO recipients and donor PVG rats were 10 to
12 weeks of age. The animal studies were approved by the
Animal Care Committee of the Royal Netherlands Academy of
Arts and Sciences and conformed to the tenets of the ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research.
Anesthesia
Donor rats were killed by an intracardial injection of pentobar-
bital (0.5 ml; Euthesate; Apharmo, Arnhem, The Netherlands).
Recipients were anesthetized by an intramuscular injection of
a mixture of fluanisone and fentanyl citrate (0.5 ml/kg; Hyp-
norm; Janssen Pharmaceutica, Beerse, Belgium) and an intra-
peritoneal injection of diazepam (2.5 mg/kg). Oxybuprocaine
hydrochloride (0.4%) was used for topical anesthesia of the
cornea.
Orthotopic Corneal Transplantation
Full-thickness corneal transplantations were performed in the
right eye of the recipient rat using a technique previously
described.10 Briefly, before surgery dilation of the iris was
obtained by subcutaneous injection of atropine sulfate (0.15
mg/kg) and topical administration of atropine 1% sulfate and
10% phenylephrine hydrochloride. With a 3-mm trephine and
curved Vannas scissors, the corneal button was removed from
the donor and recipient rats. The donor cornea was stored in
Eagle’s modified essential medium with 2% fetal calf serum,
100 IU/ml penicillin and 100 mg/ml streptomycin (Life Tech-
nologies, Breda, The Netherlands) until use. Eight stitches were
made using a continuous 10-0 monofilament nylon suture (Al-
con, Fort Worth, TX) to secure the donor button into the
recipient graft bed. After surgery, no attempt was made to
re-form the anterior chamber or to remove the suture.
Clinical Evaluation
Grafts were observed for occurrence of graft rejection using an
operating microscope, on each alternate day until POD 14 and
once a week thereafter. Rejection was diagnosed as an opacity
score of 3 or higher in a previously clear graft. Opacity was
scored from 0 to 4. A score of 3 meant that the iris vessels were
not visible, but the pupil margins could be distinguished.9
Corneal transplantations that were complicated by technical
failures were excluded from the study, as well as grafts that had
an opacity score of 3 or higher during clodronate liposome
injections (see experimental design).
Preparation of Clodronate Liposomes
Clodronate liposomes were prepared as has been described.13
In short, 75 mg phosphatidylcholine and 11 mg cholesterol
were dissolved in chloroform and a thin lipid film was pro-
duced by low-vacuum rotary evaporation. This film was dis-
persed in 10 ml phosphate-buffered saline (PBS) solution in
which 1.8 to 1.9 ml dichloromethylene diphosphonate (clo-
dronate [Cl2MDP]; the kind gift of Boehringer Mannheim,
Mannheim, Germany) was dissolved. The suspension was
maintained at room temperature for 2 hours followed by son-
ication for 3 minutes in a water bath sonicator. After another 2
hours at room temperature, the dichloromethylene diphospho-
nate liposome suspension was centrifuged at 100,000g for 30
minutes to remove free dichloromethylene diphosphonate.
The liposomes were resuspended in 4 ml PBS and stored at 4°C
until use.
Experimental Design
Ninety-one transplantations were performed of which five
were excluded: four because of technical failures of the trans-
plantations, such as extensive synechiae and hyphema, and
one because of an anesthesia problem. Four of the transplan-
tations were autografts. The allografted animals were divided
into two experimental groups: an untreated and a clodronate
liposome–treated group. The latter received subconjunctival
injections of clodronate liposomes immediately after transplan-
tation and on PODs 2, 4, 6, and 8. At each time point 100 ml of
these liposomes was injected near the limbus, dispensed over
four locations (625 ml each), to achieve an equal distribution
around the cornea. Previously, it had been demonstrated that
during clodronate liposome injections the graft became slightly
more opaque than the untreated grafts.10 It was found that an
opacity score of three or higher was not acceptable, because
the graft will not regain clarity after POD 8. For this reason, 3
of the 41 clodronate liposome–treated animals had to be ex-
cluded from the study because the graft rejection time could
not be determined. In these rats, failure was thought to be due
to mechanical reasons, such as liposome clotting or increased
pressure around the eyeball. An immunologic cause for rejec-
tion seems improbable so soon after grafting in an avascular
cornea and had never occurred this early in the untreated
group.
Experiment 1. Twenty-one grafts were observed for the
appearance of graft rejection for 100 days. The four autografts
in AO recipients were used to test for the correct transplanta-
tion technique and the nine untreated allografts to determine
the rejection time. Eight allogeneic grafts were treated with
clodronate liposomes to determine whether this treatment also
prevents graft rejection in the PVG-AO rat strain combination.
Experiment 2. To determine the immunologic basis for
the absence of graft rejection after clodronate liposome treat-
ment, rats were killed at four different time points. Two time
points were chosen before rejection occurred in the untreated
allogeneic group (PODs 3 and 7), one at the onset of graft
rejection in the untreated allogeneic group (POD 12) and
approximately one 5 days after rejection (POD 17). Lymphoid
cells were isolated from three locations to determine the pres-
ence of CTLs: the submandibular lymph nodes (SLNs), the
mesenteric lymph nodes (MLNs), and the spleen. To analyze
for the presence of alloantibodies, serum was obtained at these
same time points. All serum samples were heat-inactivated and
stored at 220°C in small aliquots until use.
Experiment 3. To exclude the possibility that local ad-
ministration of clodronate liposomes suppresses the whole
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immune system, five AO rats were immunized intraperitoneally
with PVG lymphocytes. Three of them were treated with
subconjunctival injections of clodronate liposomes on the day
of immunization and 2, 4, 6, and 8 days later; the other two rats
remained untreated. Ten days after immunization, rats were
killed, and the presence of CTLs and antibodies directed to-
ward PVG lymphocytes was tested in a chromium-release assay
and an immunofluorescence assay.
Cell-Mediated Cytotoxicity Assay
The specific cytotoxic activity of lymphoid cells derived from
grafted rats was determined by a chromium 51 release assay.
Cells isolated from the SLNs, MLNs, and spleen were measured
separately. Single-cell suspensions were prepared by gently
teasing the tissue through a nylon-mesh strainer (70-mm Cell
Strainer; Falcon, Becton Dickinson, Franklin Lakes, NJ). The
cell suspensions were washed twice and resuspended in cul-
ture medium (RPMI 1640 containing 2.0 mM L-glutamine, 10
mM HEPES buffer [Life Technologies], 100 IU/ml penicillin,
100 mg/ml streptomycin, 10% heat-inactivated fetal calf serum
[Life Technologies], and 3 3 1025 M 2-mercaptoethanol
[Sigma, St. Louis, MO]) at a concentration of 5 3 106 cells/ml.
Thymocytes derived from a young naive PVG rat were pre-
pared as described and irradiated (30 Gy) with a cesium 137
source. These irradiated stimulator cells were adjusted to a cell
concentration of 5 3 106 cell/ml; 0.5 ml of the suspension was
mixed with 1 ml effector cells in 24-well trays (Costar, Cam-
bridge, MA), total volume 1.5 ml; and cells were incubated at
37°C in a humidified 5% CO2 atmosphere. After 5 days the
effector cells from six identical wells were pooled, and cell
viability was determined by trypan blue exclusion. Cells were
centrifuged at 200g for 10 minutes and resuspended in culture
medium at the following concentrations: 10 3 106/ml; 5 3
106/ml; 2.5 3 106/ml and 1.25 3 106/ml.
SLNs and MLNs from a naive PVG rat served as target cells.
Target cells were cultured for 5 days in culture medium at a
concentration of 5 3 106 cells/ml, and after 2 days in culture
concanavalin A (ConA 2 mg/ml; Life Technologies) was added.
On the day of the assay, target cells were washed and labeled
with 100 mCi Na2
51CrO4 (Amersham, Little Chalfont, UK) at
37°C for 1 hour. Labeled cells were washed three times with
culture medium, incubated for 30 minutes in 20 ml culture
medium to remove spontaneously released 51Cr, centrifuged
(10 minutes, 200g) and resuspended at a concentration of 2 3
105 cells/ml. Fifty microliters of labeled target cells (104 cells)
were plated into wells of round-bottomed 96-well microtiter
plates (Costar). One hundred microliters of effector cells in
different concentrations was added in triplicate to the target
cells. Effector-to-target ratios ranged from 100:1 to 12.5:1.
Plates were centrifuged at 100g for 3 minutes, followed by a
4-hour incubation at 37°C in a humidified 5% CO2 atmosphere.
After 4 hours, the plates were centrifuged for 10 minutes at
500g and 100 ml supernatant was removed from each well for
counting of radioactivity in a spectrometer (Auto-gamma; Pack-
ard, Meriden, CT). The cytotoxicity of each sample was deter-
mined as follows:
Percentage specific 51Cr release
5
experimental release 2 spontaneous release
maximal release 2 spontaneous release
3 100
Spontaneous release was determined by counting supernatants
from wells containing target cells and culture medium only.
The maximum release was determined by counting the super-
natant of wells containing target cells and 1% Triton X-100
(Sigma). The CTL assays were tested each time for reproduc-
ibility with cell suspensions derived from the SLNs, MLNs, and
spleen of naive AO rats and of AO rats that had been immu-
nized against alloantigens by repeated intraperitoneal injec-
tions with PVG lymphocytes and splenocytes.
Assay of Alloantibodies in Serum
The presence of specific antibodies against PVG cells was
tested by indirect immunofluorescence assay. PVG lympho-
cytes were isolated and cultured for 3 days in the presence of
ConA (2 mg/ml) to increase their size and enhance their major
histocompatibility complex (MHC) expression. After 3 days,
the cells were washed and fixed with 2% paraformaldehyde.
Subsequently, these fixed cells were washed twice in washing
medium (PBS, 1% bovine serum albumin [Sigma], and 0.2%
sodium azide), centrifuged for 10 minutes at 200g, and resus-
pended at 5 3 106 cells/ml. Ten microliters serum was added
to 90 ml of these cells. After an incubation for 1 hour, cells
were washed and incubated for another hour at 4°C with a
1:50 dilution of rabbit anti-rat Ig antibody labeled with fluores-
cein isothiocyanate (Rara-Ig-FITC; Nordic, Tilburg, The Neth-
erlands). Cells were washed once, 1 drop of Evans blue was
added to the pellet, and cells were washed again. Finally, they
were suspended in PBS-glycerol, a drop of Vectashield (Vector;
Burlingame, CA) was added, and they were mounted on a glass
slide with a coverslip. The cells were scored for the presence
of immunofluorescence-positive cells by a masked observer,
and the percentage of positive cells was calculated. In each
assay, sera from grafted rats and samples from a pool of naive
AO rats or from a pool of AO rats immunized against PVG
antigens were included.
Assay of Complement-Dependent Alloantibody
in Serum
To test the specific cytotoxic activity of the serum samples a
chromium release assay was used. The Cr 51-labeled target
cells were prepared as described. Fifty microliters of these cells
(5 3 106 cells/ml) was plated into wells of a round-bottomed
96-well plate and incubated at 37°C for 60 minutes with 50 ml
serum dilution (1:10, 1:20, 1:40, and 1:80) obtained from
graft-recipient rats. Subsequently, 50 ml fresh normal rat serum
was added, as a source of complement, and the incubation
continued for 60 minutes. The plates were then centrifuged at
500g for 10 minutes, and 100 ml of the supernatant was re-
moved and counted in a gamma counter. The percentage of
specific release of serum samples was determined as described.
In each assay, a serum sample from a pool of naive AO rats and
a serum sample from a pool of AO rats that had been immu-
nized against PVG antigens were tested as a standard.
Statistical Analysis
The graft survival curves were compared using the log rank
test. Statistical analysis of the cytotoxic and immunofluores-
cence assays was performed using the Mann–Whitney test. The
two groups were compared at the effector-to-target ratio of 100
to 1 and serum dilution of 1:10. The statistical analyses were
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corrected for multiple comparisons; P , 0.03 was considered
statistically significant.
RESULTS
Fate of Orthotopic Corneal Grafts
Eighty-two orthotopic corneal grafts were observed for occur-
rence of graft rejection (Fig. 1). The 21 rats of experiment 1
were evaluated for the follow-up period of 100 days, whereas
the 61 rats used in experiment 2 were evaluated until they
were killed at POD 3, 7, 12 or 17.
All four autografts survived for at least 100 days. In the 40
untreated rats with a graft, no graft survival was observed
beyond 12 days (mean survival time of 10.9 days). Of the 38
allogeneic corneal grafts that were treated with clodronate
liposomes, not a single graft rejection was observed. In the
eight clodronate liposome–treated rats of experiment 1 graft
survival was prolonged beyond 100 days. In comparing the
survival times of the two groups, a significant difference of P ,
0.001 was found.
CTL Activity against Donor Antigens in Recipients
of Corneal Allografts
In experiment 2, at four time points after orthotopic allotrans-
plantation, untreated AO rats and clodronate liposome–treated
AO rats were killed to determine the presence of CTLs against
donor PVG cells. Cells were isolated from three locations to
determine differences in local and systemic CTL activity be-
tween the two groups. Local CTL activity was determined by
taking cells derived from the SLNs (Fig. 2). Comparing the two
treatment groups at the effector-to-target ratio of 100 to 1, no
difference was noted on PODs 3 and 7. But at time of the onset
of graft rejection in the untreated group, POD 12 and 5 days
later, a significant difference was noted (P 5 0.006 and P 5
0.008, respectively). Far higher CTL activity was found in the
untreated rats than in the clodronate liposome–treated rats.
The second more remote location investigated for pres-
ence of CTLs was the MLNs. No difference was detected at any
of the four postoperative time points (Fig. 3). The spleen was
assayed for presence of systemic CTL activity, and a pattern
similar to that in the local lymph nodes was found (Fig. 4).
Before graft rejection in the untreated group, no activity was
present, but at the time of graft destruction, significantly more
CTL activity was present in the spleen of untreated rats than in
treated rats. A difference was demonstrated at POD 12 (P 5
0.008) and later at POD 17 (P 5 0.009).
Alloantibody Response against Donor Antigens in
Recipients of Allografts
The presence of antibodies directed toward donor PVG cells
was tested in an indirect immunofluorescence assay. Results
from sera of allografted rats are shown in Table 1. In contrast
to the differences found between the two treatment groups in
CTL activity, a significant difference was detected only on POD
17 (P , 0.01). At that postoperative time point a higher
percentage of alloantibodies was circulating in the blood of
untreated allografted rats.
Complement-Dependent Cytotoxic Activity
against Donor Antigens in Recipients
of Allografts
To determine whether there was a difference in the presence
of complement-dependent cytotoxic antibodies between the
two groups, particularly on POD 17, chromium-release assays
were performed. Four serum dilutions at the four different time
points were tested. As was to be expected, no detectable
cytotoxic activity was found in any of the serum samples, in
clodronate liposome–treated rats, or in untreated rats on PODs
3, 7, and 12. Moreover, on POD 17, no cytotoxic antibodies
were detectable in the serum of untreated allografted rats. The
results obtained for the serum dilution 1:10 are summarized in
Table 1.
Effect of Subconjunctival Administration of
Clodronate Liposomes on Immune Responses
to Intraperitoneally Injected
Allogeneic Lymphocytes
After intraperitoneal injections of PVG lymphocytes, high CTL
responses were detected in SLNs and MLNs in untreated and
clodronate liposome–treated rats (Table 2). Also, the genera-
tion of complement-dependent antibodies was not downregu-
lated by subconjunctival injections of clodronate liposomes in
systemically immunized rats (Table 3).
DISCUSSION
It has been shown that subconjunctival administration of clo-
dronate liposomes after orthotopic corneal allotransplantation
prevents graft rejection beyond 100 days in high-risk rats.10
This in vivo depletion of macrophages after transplantation
revealed that the presence of macrophages is mandatory for
FIGURE 1. Survival curves of 82 orthotopic corneal grafts in AO rats.
Three experimental groups were distinguished: AO rats receiving au-
tografts (dotted line); untreated allografted AO rats (dashed–dotted
line); and clodronate liposome–treated allografted AO rats (solid line).
A significant difference was found (P , 0.001) between the clodronate
liposome–treated allografts and the untreated allografts.
2242 Slegers et al. IOVS, July 2000, Vol. 41, No. 8
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/932908/ on 05/03/2018
the rejection process. It is unclear, however, where in this
process the clodronate liposomes are interfering.
The present study determined the influence of macro-
phage depletion on the presence of CTLs and antibodies early
after transplantation. In the first week after transplantation, no
significant difference was found between the two treatment
groups, but when the onset of graft rejection occurred in the
untreated rats (on POD 12) and on POD 17, the CTL activity
detected locally and systemically was significantly less in the
treated group. Generation of antibodies also seemed to be
impaired in macrophage-depleted rats.
In our model, graft rejection seemed to correlate with
increase of CTL activity in the local lymph nodes and the
spleen on POD 12 and 17. Although corneal graft rejection is
possible in the absence of CD81 CTLs,14,15 it has been shown
that rejection can be accompanied by high CTL responses in
local lymph nodes or spleen.16–18 These CTL activities are
detected by an in vitro assay. How these specific CTLs directed
toward donor antigens are induced remains speculative, be-
cause corneal grafts are thought to be free of antigen-present-
ing cells. Therefore, the direct route seems improbable. The
generation of CTL activity probably occurs mostly through the
indirect pathway. It has been shown that preculturing is man-
datory to measure CTL responses in these rats.18
Van der Veen et al.18 tested the same locations for pres-
ence of cytotoxic activity toward donor antigens in macro-
phage-depleted rats after the onset of rejection had occurred.
Although no difference was detected in local CTL activity,
macrophage depletion downregulated CTL activity in the
MLNs as well as the spleen. The results, obtained from both
local and more remote lymph nodes, are in slight contrast with
findings in the current study. Also the difference found be-
tween the two groups was more pronounced in the current
study. A possible explanation for these findings may be the use
of a different rat strain combination and/or the induction of
keratitis before transplantation by van der Veen et al. The eight
clodronate liposome–treated allogeneic grafts performed in
our experiment 1 demonstrated that administration of clo-
dronate liposomes is also effective in prolonging graft survival
in this rat strain combination for at least 100 days. Although the
CTL response was more vigorous in these untreated rats, it was
still downregulated and graft rejection prevented by macro-
phage depletion. Early rejection after small bowel allotrans-
plantation is also characterized by a massive influx of macro-
phages.19 In this type of solid graft rejection the macrophages
seem to be mandatory as well, because intraperitoneal injec-
tion of clodronate liposomes prolonged graft survival.20 Al-
though the precise role of the macrophage in the graft rejec-
FIGURE 2. Effect of clodronate liposome treatment on CTL responses in the SLNs on POD 3 (A); POD 7 (B); time of onset of graft rejection in the
untreated allografts, POD 12 (C); and POD 17 (D). Values represent the mean percentage of specific release 6SD of five to seven rats per group.
The clodronate liposome–treated group (solid line) was compared with the untreated allografted group (dotted line) at the effector-to-target ratio
of 100:1. A significant difference was observed at POD 12 (P 5 0.006) and POD 17 (P 5 0.008). The same procedure was followed for the assays
described in Figures 3 and 4.
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tion process is unknown, their presence is required for
inducing donor-directed cytotoxicity responses by intestinal
epithelial cells.21
Another effect of the clodronate liposomes was inhibition
of antibody production. Our model showed that in untreated
rats, antibodies against donor antigens were detectable 5 days
after the onset of graft rejection using an immunofluorescence
assay. Unfortunately, it was not possible technically to perform
an antibody-dependent cell-mediated cytotoxicity (ADCC) as-
say, but because the results of the chromium-release assay
show that these antibodies were not complement dependent,
these results indirectly suggest that they may be cell-dependent
cytotoxic antibodies. Van der Veen et al.18 also showed that
macrophage depletion impairs generation of complement-de-
pendent antibodies after corneal transplantation. Lung allo-
transplantation leads to production of both types of antibodies.
Depleting donor macrophages before transplantation by intra-
tracheal instillation of clodronate liposomes does not prolong
graft survival, but the antibodies involved, both in ADCC
and complement-dependent cytotoxicity are significantly de-
creased.22 Also the presence of these antibodies is found in
chronic rejection of cardiac allografts and is related to activa-
tion of macrophages.23
As mentioned earlier, corticosteroids have been found to
be very effective in preventing graft rejection, but aside from
the fact that not all rejections can be inhibited, this drug also
has many side effects. In the attempt to find new therapeutic
regimens, an important goal is the absence of systemic side
effects. A major concern about the mechanism by which clo-
dronate liposomes work could be that macrophage depletion
was accomplished not only locally but also systemically. Ex-
periment 3 showed that subconjunctival injection of clo-
dronate-containing liposomes, using the same procedure as
was used after corneal transplantation, did not interfere with
the cellular and humoral immune response in rats injected
intraperitoneally with allogeneic lymphocytes. Probably only
the conjunctival macrophages are depleted with this proce-
dure. Van Klink et al.2 showed that in Chinese hamsters,
repeated subconjunctival injections with clodronate liposomes
led to depletion of acid phosphatase–positive macrophages in
the conjunctiva. By contrast, the number of acid-phosphatase–
positive cells in the corneal epithelium, stroma, ciliary body,
and iris was not affected.24 An explanation for this could be
that redistribution of liposomes after local injection is hindered
by the anatomic features of the cornea.25
Another point for concern could be that liposome treat-
ment affects not only the macrophage population but also the
dendritic cell population. No experimental studies have been
published so far in which the number of dendritic cells or the
function of the dendritic cell population is measured after
subconjunctival injections of clodronate liposomes. It has been
shown, however, that after intravenous injections of clo-
dronate liposomes the number and distribution of dendritic
cells in the spleen is not affected. Also the antigen-presenting
FIGURE 3. Effect of clodronate liposome treatment on CTL responses in MLNs. No significant difference was observed.
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cell activity of splenocytes and lymph node cells, measured by
in vitro primary CTL responses to ovalbumin or mixed lympho-
cyte reactions to allogeneic antigens, were comparable in clo-
dronate liposome–treated and untreated mice.26,27 After intra-
peritoneal injections with clodronate liposomes, these mice
showed similar flow cytometry analysis data for dendritic cells
as the control PBS-liposome treated group.28
Using the corneas from the rats used in this study, Torres
et al.29 determined the effect of administration of local clo-
dronate liposome on cytokine mRNA expression within the
cornea. In the macrophage-depleted rats, decreased expression
of interleukin (IL)-1b, IL-2, IL-4, IL-6, interferon (IFN)-g, and
tumor necrosis factor (TNF)-b/lymphotoxin (LT) mRNA was
found. Treatment with clodronate liposomes after corneal
grafting thus resulted in decreased local mRNA expression of
several macrophage-derived cytokines and T-cell derived cyto-
kines and reduced levels of CTLs and antibodies.
The mechanism by which the clodronate liposomes in-
duce immunosuppression remains highly speculative. From
the fact that clodronate liposomes interfere with only the
macrophage population, several hypotheses can be proposed.
Because no effector mechanisms, such as CTLs and antibody
production, are present, it could be concluded that there is an
interruption in the afferent arc of the immune response leading
FIGURE 4. Effect of clodronate liposome treatment on CTL responses in spleen. A significant difference was observed at POD 12 (P 5 0.008) and
POD 17 (P 5 0.009).
TABLE 1. Effect of Clodronate Liposomes on Humoral Immune Response after Orthotopic Transplantation
POD 3 POD 7 POD 12 POD 17
LIP Untreated LIP Untreated LIP Untreated LIP Untreated
Antibodies* 2 6 2 2 6 3 2 6 3 2 6 2 3 6 1 4 6 1 3 6 3‡ 36 6 12
Complement-dependent
antibodies† 0 6 0 0 6 0 1 6 1 0 6 0 1 6 1 0 6 0 2 6 1 3 6 5
Alloantibody response, toward PVG lymphocytes, in AO rats after orthotopic allotransplantation. Clodronate liposome–treated rats (LIP) are
compared with untreated rats at different PODs for the serum dilution 1:10. Values are presented as mean 6 SD.
* Immunofluoresence assay (percentage positive staining cells).
† Chromium release assay (percentage specific 51Chromium release).
‡ P , 0.01.
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to graft rejection. Macrophages can display a variety of func-
tions that can be immunosuppressive or stimulatory. They are
able to present antigen, but less so than dendritic cells or
Langerhans’ cells.27 Our hypothesis is that macrophages inter-
act with dendritic cells, and the antigen-presenting function of
this latter cell is therefore enhanced. Interaction of lung mac-
rophages with dendritic cells to present antigenic peptides has
been reported. Depending on the ratio of interstitial macro-
phages to dendritic cells, the dendritic cell function is either
augmented or inhibited.30 Alternatively, macrophages can me-
diate with the influx of T cells through upregulation of adhe-
sion molecules or production of cytokines by the macrophage
population, T cells are attracted to enter the inflammatory site.
Fox et al.26 showed that macrophage depletion after xenograft-
ing in nonobese diabetic mice leads to reduced graft infiltration
by T lymphocytes and eosinophils without directly affecting
the function of the T cells or the dendritic cells. Van der Veen
et al.18 also showed an decreased influx of immunocompetent
cells into the graft of clodronate-treated rats after corneal
allotransplantation and the expression of intercellular adhesion
molecule (ICAM)-1 and leukocyte function–associated antigen
(LFA)-1 is significantly reduced in these clodronate liposome–
treated rats compared with untreated rats.18,31
At this moment a study is in progress to determine the
delayed-type hypersensitivity responses of clodronate-treated
animals after orthotopic corneal allotransplantation. Results of
this study will resolve the question of whether antigen presen-
tation has occurred and the effector phase of rejection has
started in these clodronate liposome–treated animals.
Our study shows that after corneal allotransplantation in
untreated rats, high CTL responses are detected locally and
systemically, as well as complement-independent antibodies at
time of rejection. We conclude that macrophage depletion,
through repeated subconjunctival injections of clodronate li-
posomes, downregulates these high CTL responses and impairs
antibody formation.
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